Forest and Merz settle Namenda litigation

Published: 27-Jul-2010
Finance

Generic versions of drug to enter market in 2015


Pharmaceutical developer Forest Laboratories of the US and partner Merz Pharmaceuticals of Germany have signed a patent litigation settlement agreement with 10 firms that were seeking to launch generic versions of Alzheimer’s drug Namenda (memantine hydrochloride) immediate release tablets.

Under the settlement agreements, the first generic versions of memantine will enter the market on 11 January 2015. This settlement agreement is subject to review by the US Federal Trade Commission.

Forest and Merz will provide licenses to Amneal, Watson, Dr. Reddy’s, Lupin, Mylan, Orchid, Sun, Teva, Upsher-Smith, and Wockhardt.

  • Companies:
  • Forest Laboratories Inc
  • Dr Reddys Laboratories
  • Wockhardt Group
  • Merz
See more

You may also like

Finance

Acino and Merz Therapeutics sign Ukraine distribution agreement

Read more
Under the agreement, Acino will commercialise the product portfolio of Merz Therapeutics in the areas of gastroenterology, neurology and dermatology

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Acino and Merz Therapeutics sign Ukraine distribution agreement

Under the agreement, Acino will commercialise the product portfolio of Merz Therapeutics in the areas of gastroenterology, neurology and dermatology
Manufacturing

Dr. Reddy’s and TR-Pharm announce strategic collaboration in Turkey

Dr. Reddy’s and TR-Pharm have entered into a strategic collaboration agreement to manufacture and commercialise a portfolio of biosimilar drugs in Turkey
Research & Development

Dr Reddy’s raises its R&D spending

Biosimilars account for around 15–20% of the overall R&D spend, representing US$45–60m
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Finance

Operating margins expected to grow by 28% year-on-year for Indian pharma firms

Most are focusing on niche products in the US
Finance

Actavis completes US$28bn purchase of Forest Laboratories

Names new management team
Finance

Actavis to acquire Forest Laboratories for US$25bn

Creates a company with US$15bn in revenue and a growing $7bn North American speciality brand business
Subscribe now